Recent Updates
Recently added Catalysts
NVAX Neutral Sentiment Score: 60/100

Novavax to Participate in the BofA Securities 2023 Health Care Conference

Thursday, May 4, 2023 1 min read
Key Takeaway: Novavax, Inc. announced its participation in the BofA Securities 2023 Health Care Conference, scheduled for May 10-11, 2023, in Las Vegas, Nevada. Key company representatives, including the CEO and the President of Research & Development, will be involved in discussions. The conference serves as a platform for investor meetings and includes a fireside chat, which will be made available for replay on their website. Novavax continues to focus on developing vaccines for COVID-19, influenza, and combined strains.

Market Sentiment Analysis

POSITIVE FACTORS

  • Novavax is participating in a prominent health care conference.
  • The company is advancing innovative protein-based vaccines.
  • The event includes key leaders from the company.

Full Press Release Details

GAITHERSBURG, Md., May 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the BofA Securities 2023 Health Care Conference.
Conference Details:
Fireside Chat
Date: Thursday, May 11, 2023
Time: 10:00 – 10:30 a.m. Pacific Daylight Time (PDT)
Location: Encore Hotel in Las Vegas, Nevada
Moderator: Alec Stranahan, Ph.D., Equity Research Analyst – Biotechnology
Novavax participants: John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development
Conference
Event: Investor Meetings
Date: Wednesday, May 10, 2023 - Thursday, May 11, 2023
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined.
Please visit novavax.com and LinkedIn for more information.
Erika Schultz | 240-268-2022
Ali Chartan or Giovanna Chandler | 240-709-5563
SOURCE Novavax, Inc.

21 %

more press release views with

Frequently Asked Questions

When is Novavax participating in the BofA Securities Conference?

Novavax will participate on May 11, 2023, from 10:00 - 10:30 a.m. PDT.

Who will moderate Novavax's fireside chat at the conference?

The fireside chat will be moderated by Alec Stranahan, Ph.D.

What is Novavax's focus in vaccine development?

Novavax focuses on vaccines for COVID-19, influenza, and their combination.

How can I access the recorded fireside session?

The recorded session will be available on Novavax's Events page for 90 days.

Where is Novavax based?

Novavax is based in Gaithersburg, Maryland, USA.

Tags: NVAX Viatris Investor Conferences Healthcare Novavax BofA Securities health care conference vaccines COVID-19
Last updated: May 4, 2023